The GLP-1 receptor agonist revolution comes to nephrology

IF 28.6 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Nephrology Pub Date : 2024-07-29 DOI:10.1038/s41581-024-00876-4

Merlin C. Thomas, Mark E. Cooper

引用次数: 0

Abstract

Glucagon-like peptide 1 receptor agonists improve glucose control, promote weight loss and reduce the risk of major cardiovascular events in people with type 2 diabetes mellitus. The FLOW study now provides unequivocal evidence of kidney protective effects with semaglutide in adults with type 2 diabetes mellitus and chronic kidney disease.

查看原文本刊更多论文

肾脏病学迎来 GLP-1 受体激动剂革命

胰高血糖素样肽 1 受体激动剂可改善 2 型糖尿病患者的血糖控制、促进减肥并降低发生重大心血管事件的风险。现在，FLOW 研究提供了明确的证据，证明semaglutide 对患有 2 型糖尿病和慢性肾病的成人具有肾脏保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Nephrology 医学-泌尿学与肾脏学

CiteScore

39.00

自引率

1.20%

发文量

127

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Nephrology aims to be the premier source of reviews and commentaries for the scientific communities it serves. It strives to publish authoritative, accessible articles. Articles are enhanced with clearly understandable figures, tables, and other display items. Nature Reviews Nephrology publishes Research Highlights, News & Views, Comments, Reviews, Perspectives, and Consensus Statements. The content is relevant to nephrologists and basic science researchers. The broad scope of the journal ensures that the work reaches the widest possible audience.